The Wörwag Pharma Hungarian subsidiary was established in 1993. We’ve cultivated a philosophy that centers on patients, personal contact with doctors and pharmacists, and a supportive, collaborative corporate culture that defines our commitment towards patient wellbeing.
Created in 1965, our parent company, Wörwag Pharma GmbH & Co.KG is now operating in 40 countries and distributing products to over 104 international destinations, while managing to maintain the values of a family business. The future goals are determined by the basic philosophy: self-developed products and expertise, and OTC and generic medicines intended to enhance the well being of patients.
For 40 years Wörwag Pharma stands for competence and expertise in the fields of biofactors and generics. We have established our reputation here as a specialist in the treatment of diabetes and its accompanying disorders.
Biofactors (vitamins and mineral supplements), preparations for polyneuropathy, and generics with excellent cost-benefit ratios: the broad product range of Wörwag Pharma. High quality medication, modern active substances and successful use of the medications in advanced therapeutic concepts in the fields of diabetic accompanying disorders confirm that Wörwag Pharma is an expert partner in science and practice.
Thinking and working globally is not a marketing strategy as far as we are concerned, but a way of living our profession every day – and it is at the same time, a challenge. Our task every day is to overcome long distances and cultural differences. With success!
Contact
1021 Budapest, Hűvösvölgyi út 54.
Tel: +36 (1) 345 7350
Fax: +36 (1) 345 7353
E-mail: info@woerwagpharma.hu
The managing director of Wörwag Pharma Hungary, Dr. Éva Kádár depicts the company’s impressive evolution, highlighting the expansive network of neuropathy centers that they’ve helped establish all over Hungary and…
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
